{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:31:36Z","timestamp":1790519496501,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T00:00:00Z","timestamp":1515456000000},"content-version":"vor","delay-in-days":373,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Aurexel Life Sciences Ltd."}],"content-domain":{"domain":["cancercell.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ccell.2016.12.003","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T15:17:42Z","timestamp":1483975062000},"page":"64-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"title":["Simultaneous Inhibition of PI3K\u03b4 and PI3K\u03b1 Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-\u03baB and AKT"],"prefix":"10.1016","volume":"31","author":[{"given":"Juliane","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Soujon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje M.","family":"Wengner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Zitzmann-Kolbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sturz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Haike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh Hui","family":"Keng Magdalene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze Huey","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Yong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Mumberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Thye","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Ziegelbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2016.12.003_bib1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2016.12.003_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.ccell.2016.12.003_bib3","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1182\/blood.V122.21.1832.1832","article-title":"The potent PI3K-\u03b4,\u03b3 inhibitor, IPI-145, exhibits differential activity in diffuse large B-cell lymphoma (DLBCL) cell lines","volume":"122","author":"Campbell","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2016.12.003_bib4","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1073\/pnas.1411701111","article-title":"Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors","volume":"111","author":"Ceribelli","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2016.12.003_bib5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ccell.2016.12.003_bib6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2016.12.003_bib7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.molimm.2004.04.008","article-title":"B cell antigen receptor signaling 101","volume":"41","author":"Dal Porto","year":"2004","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ccell.2016.12.003_bib8","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/0008-5472.CAN-04-4058","article-title":"Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors","volume":"65","author":"Dasgupta","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2016.12.003_bib9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2016.12.003_bib10","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.ccr.2012.11.003","article-title":"MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in\u00a0vitro and in\u00a0vivo","volume":"22","author":"Fontan","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2016.12.003_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V116.21.55.55","article-title":"CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 {delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts","volume":"116","author":"Furman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2016.12.003_bib12","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/ijc.29579","article-title":"Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells","volume":"137","author":"Gockeritz","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ccell.2016.12.003_bib13","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2016.12.003_bib14","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell\u2013like diffuse large B-cell lymphoma cells","volume":"111","author":"Mathews Griner","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2016.12.003_bib15","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1158\/0008-5472.CAN-13-3274","article-title":"B-cell expansion and lymphomagenesis induced by chronic CD40 signaling is strictly dependent on CD19","volume":"74","author":"Hojer","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2016.12.003_bib16","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2016.12.003_bib17","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2016.12.003_bib18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.1008969108","article-title":"Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells","volume":"108","author":"Kloo","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2016.12.003_bib19","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.molimm.2010.12.007","article-title":"Regulation of BCR signaling","volume":"48","author":"Kurosaki","year":"2011","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ccell.2016.12.003_bib20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2016.12.003_bib21","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ccell.2016.12.003_bib22","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1158\/1535-7163.MCT-05-0049","article-title":"Inhibition of the phosphatidylinositol 3-kinase\/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis","volume":"5","author":"Liu","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2016.12.003_bib23","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models","volume":"12","author":"Liu","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"suppl","key":"10.1016\/j.ccell.2016.12.003_bib24","article-title":"PI3K\u03b1\/\u03b4 inhibition has greater efficacy compared to PI3K\u03b4-selective inhibition in NHL with activated NF\u03baB pathway","volume":"73","author":"Liu","year":"2013","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ccell.2016.12.003_bib25","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2016.12.003_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11899-012-0142-1","article-title":"GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia","volume":"8","author":"Macias-Perez","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.ccell.2016.12.003_bib27","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/0008-5472.CAN-10-2525","article-title":"Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas","volume":"71","author":"Naylor","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2016.12.003_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2016.12.003_bib29","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous Pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2016.12.003_bib30","doi-asserted-by":"crossref","first-page":"11936","DOI":"10.1073\/pnas.1005667107","article-title":"Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression","volume":"107","author":"Petersen","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2016.12.003_bib31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri2036","article-title":"PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?","volume":"7","author":"Rommel","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ccell.2016.12.003_bib32","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/cmdc.201600148","article-title":"Discovery and SAR of novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: identification of copanlisib (BAY 80-6946)","volume":"11","author":"Scott","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ccell.2016.12.003_bib33","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2016.12.003_bib34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1042\/BJ20112092","article-title":"PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances","volume":"442","author":"So","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.ccell.2016.12.003_bib35","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1182\/blood.V118.21.2716.2716","article-title":"The Bruton\u2019s tyrosine kinase (BTK) inhibitor PCI-32765 modulates chronic active BCR signaling and induces tumor regression in relapsed\/refractory ABC DLBCL. ASH Annual Meeting","volume":"118","author":"Staudt","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2016.12.003_bib36","doi-asserted-by":"crossref","first-page":"484537","DOI":"10.1155\/2015\/484537","article-title":"Constitutive NF- kappa B activation underlines major mechanism of drug resistance in relapsed refractory diffuse large B cell lymphoma","volume":"2015","author":"Turturro","year":"2015","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.ccell.2016.12.003_bib37","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1182\/blood-2006-04-016907","article-title":"Role of phosphatidylinositol 3'-kinase\/AKT pathway in diffuse large B-cell lymphoma survival","volume":"108","author":"Uddin","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2016.12.003_bib38","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610816305980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610816305980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T15:22:51Z","timestamp":1601306571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610816305980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1535610816305980"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2016.12.003","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727191240.793529042","asserted-by":"object"}]},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous Inhibition of PI3K\u03b4 and PI3K\u03b1 Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-\u03baB and AKT","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2016.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}